The 64CAP17 antibody reacts with human IL-17A the antibody has
been reported to cross react with Rhesus monkey IL-17A, as
verified by intracellular staining experiments. The 64CAP17
antibody is a neutralizing antibody. Reactivity of the 64CAP17
antibody with other IL-17 family members has not been evaluated.
Interleukin-17A (IL-17A) is a CD4+ T cell-derived cytokine that
promotes inflammatory responses in cell lines and is elevated in
rheumatoid arthritis, asthma, multiple sclerosis, psoriasis, and
transplant rejection. The cDNA encoding human IL-17A was isolated
from a library of CD4+ T cells the encoded protein exhibits 72
percent amino acid identity with HVS13 , an open reading frame
from a T lymphotropic Herpesvirus saimiri, and 63 percent with
mouse CTLA-8 (cytotoxic T-lymphocyte associated antigen-8). Human
IL-17A exists as glycosylated 20-30 kD homodimers. High levels of
IL-17A homodimer are produced by activated peripheral blood CD4+
T-cells. IL-17A enhances expression of the intracellular adhesion
molecule-1 (ICAM-1) in human fibroblasts. Human IL-17A also
stimulates epithelial, endothelial, or fibroblastic cells to
secrete IL-6, IL-8, G-CSF, and PGE2. In the presence of human
IL-17A, fibroblasts can sustain the proliferation of CD34+
hematopoietic progenitors and induce maturation into neutrophils.
Mouse, rat, and human IL-17A can induce IL-6 secretion in mouse
stromal cells, indicating that all homologs can recognize the
mouse IL-17A receptor. IL-23-dependent, IL-17A-producing CD4+ T
cells (Th-17 cells) have been identified as a unique subset of Th
cells that develops along a pathway that is distinct from the
Th1- and Th2- cell differentiation pathways. The hallmark
effector molecules of Th1 and Th2 cells, e.g., IFN-g and IL-4,
have each been found to negatively regulate the generation of
these Th-17 cells. Additionally, activated human CD4+ T cells
have been found to produce the IL-17A/F heterodimer, as well as
the corresponding homodimers. In comparing the relative potency
of IL-17A, IL-17F, and IL-17A/F, all three were found to induce
GRO-a secretion IL-17A was most potent, followed by IL-17A/F
heterodimer, then IL-17F (100fold lower than IL-17A). 64CAP17 can
be used to detect IL-17 heterodimers by immunoprecipitation
followed by immunoblot with anti-IL17F monoclonal antibody. The
64CAP17 has been shown to react to rhesus and marmoset primates.